Active Surveillance in Men With Localized Prostate Cancer Full Text
Annals of Internal Medicine,  Clinical Article

Dahabreh IJ et al. – Evidence is insufficient to assess whether Active surveillance (AS) is an appropriate option for men with localized prostate cancer. A standard definition of AS that clearly distinguishes it from watchful waiting (WW) is needed to clarify scientific discourse.

Methods
  • MEDLINE and Cochrane databases (from inception to August 2011).
  • Screened abstracts and reviewed full-text publications to identify eligible studies.
  • One reviewer extracted data, and another verified quantitative data.
  • Two independent reviewers rated study quality and strength of evidence for comparative effectiveness.
  • Sixteen independent cohorts defined AS, 42 studies evaluated factors that affect the use of observational strategies, and 2 evidence reports and 22 recent studies reported comparisons of WW versus treatment with curative intent.
  • The most common eligibility criteria for AS were tumor stage (all cohorts), Gleason score (12 cohorts), prostate-specific antigen (PSA) concentration (10 cohorts), and number of biopsy cores positive for cancer (8 cohorts).
  • For monitoring, studies used combinations of periodic PSA testing (all cohorts), digital rectal examination (14 cohorts), and rebiopsy (14 cohorts).

Results
  • Predictors of receiving no active treatment included older age, comorbid conditions, lower Gleason score, tumor stage, PSA concentration, and favorable risk group.
  • No published studies compared AS with immediate treatment with curative intent.
  • Watchful waiting was generally less effective than treatment with curative intent; however, applicability to contemporary patients may be limited.

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

1 Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer European Journal of Cancer, August 6, 2014    Clinical Article

2 Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: The Cancer-DACUS Study Journal of Clinical Oncology, October 10, 2014    Clinical Article

3 Metformin in chemotherapy-naive castration-resistant prostate cancer: A multicenter phase 2 trial (SAKK 08/09) Full Text European Urology, August 15, 2014    Free full text    Clinical Article

4 Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial The Lancet Oncology, October 23, 2014    Clinical Article

5 Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial The Lancet Oncology, October 3, 2014    Clinical Article

6 Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): A randomised, open-label, phase 3 trial The Lancet Oncology, October 7, 2014    Clinical Article

7 Pathologic findings at risk-reducing salpingo-oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199 Journal of Clinical Oncology, September 22, 2014    Clinical Article

8 Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial The Lancet Oncology, October 20, 2014    Clinical Article

9 Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor Medical Oncology, September 22, 2014    Clinical Article

10 Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer International Journal of Cancer, September 29, 2014    Clinical Article

11 Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data The Lancet Oncology, September 24, 2014    Clinical Article

12 Lung cancer probability in patients with CT-detected pulmonary nodules: A prespecified analysis of data from the NELSON trial of low-dose CT screening The Lancet Oncology, October 9, 2014    Clinical Article

13 Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial The Lancet Oncology, September 25, 2014    Clinical Article

14 Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial The Lancet Oncology, October 8, 2014    Clinical Article

15 Salt tea consumption and esophageal cancer, a possible role of alkaline beverages in esophageal carcinogenesis International Journal of Cancer, September 15, 2014    Clinical Article

16 Everolimus plus exemestane for hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer: Overall survival results from BOLERO-2 Annals of Oncology, September 30, 2014    Clinical Article

17 Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the Randomized SweDCIS Trial Journal of Clinical Oncology, October 17, 2014    Clinical Article

18 Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial The Lancet Oncology, October 30, 2014    Clinical Article

19 Screening for prostate cancer in the US? Reduce the harms and keep the benefit International Journal of Cancer, August 15, 2014    Clinical Article

20 Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): A randomised, double-blind, phase 3 trial The Lancet Oncology, October 22, 2014    Clinical Article

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore